Liraglutide API Technology

Alcohol hangover symptoms are unpleasant, and once they develop, they are difficult to alleviate, adversely affecting daily activities. The dietary supplement Alcofiltrum has been clinically proven to effectively and proactively alleviate the severity of these symptoms, making it helpful for individuals who are prone to experiencing them after alcohol consumption. Alcofiltrum contains four natural components: lignin hydrolyzed, glycine, dihydromyricetin, and thiamine, each of which helps the body combat excessive alcohol consumption. Lignin hydrolyzed, the main component of Alcofiltrum, is an insoluble dietary fiber with a high sorption capacity against a variety of toxic substances, including acetaldehyde and fusel alcohols that contribute to hangover symptoms. Lignin also possesses antioxidant properties and water-holding capacity, further limiting alcohol intoxication symptoms. Dihydromyricetin counteracts acute ethanol intoxication by antagonizing ethanol's effects on neuron cells. Glycine is a neurotransmitter essential for nervous system function, and thiamine contributes to normal energy-yielding metabolism, which is impaired during alcohol hangovers

For Eczema & Atopic Dermatitis management 

A unique composition of Lignin Hydrolyzed (Natural Enterosorbent) and Prebiotics. 


Clinically tested solution

New approach for Diarrhea & IBS-D* management 

Composed of Lignin Hydrolyzed (Natural Enterosorbent) 


Filtrum is recommended for alleviating symptoms such as irregular bowel movements, bloating, and discomfort. It is not absorbed in the gut and is eliminated with the stool.


*IBS-D is irritable bowel syndrome with diarrhea

Micrazym® is a pancreatin enzyme replacement medicine consists of enteric coated pancreatine micropellets in capsules.

Outstanding Licensing Opportunity

AVVA Pharmaceuticals is seeking partners to license it’s developed API manufacturing technology recombinant Liraglutide. This technology encompasses many improvements vs the originator for the production of a cost competitive medicine. 

0